Funding Source
NIDA Clinical Trials Network (NIH HEAL Initiative), CTN-0102-XR
UCLA
Project Period
3/2024 – 2/2026
Principal Investigator
Yih-Ing Hser, PhD (University of California, Los Angeles); Larissa Mooney, MD (University of California, Los Angeles)
Other Project Staff
Project Summary
This randomized, open-label pilot study will assess the feasibility, acceptability, and effectiveness of extended-release buprenorphine (XR-BUP, CAM2038), compared with sublingual buprenorphine-naloxone (SL-BUP) for treatment of opioid use disorder (OUD) among rural patients. Relative effectiveness of XR-BUP vs SL-BUP in rural populations with OUD has not been subjected to research, and this project seeks to rapidly develop new knowledge on the issues to support future large-scale trials. Findings will suggest possible next steps for additional research and will inform scaling of the implementation to improve capacity to utilize extended-release MOUD and increase MOUD access and uptake of extended-release MOUD in rural communities.